One of the many benefits of our medically based program is that we can offer prescription weight loss medications to our patients. They can help the body fight hunger and cravings and make patients feel fuller.
On June 4, 2021, the U.S. Food and Drug Administration (FDA) approved semaglutide for adults who suffer from obesity or are overweight under the brand name Wegovy®, Mounjaro ® or Zepbound ®. These are the first drugs for chronic weight management that has been approved since 2014.
Obesity is a chronic health issue that requires long-term management and is associated with severe health complications, including heart disease, diabetes, sleep apnea, asthma, hormonal concerns for women such as PCOS, arthritis, and certain types of cancer. Losing five to ten percent of body weight can bring impactful health benefits such as:
In combination with a high protein, reduced calorie meal plan and increased physical activity, and lifestyle changes, Semaglutide can be extremely effective in helping patients lose weight and is effective in helping patients treat type 2 diabetes.
Type 2 diabetes
Under the brand name Ozempic®, semaglutide is FDA_approved as an adjunctive therapy with diet and exercise to control blood sugar in adults with type 2 diabetes. Ozempic ® can also help reduce the risk of major cardiovascular events, such as heart attacks and stroke, in adults with type 2 diabetes and cardiovascular disease.
Changing lives with weight loss since 1984
Copyright 2025. ThinfastMD.